Innovative study provides new hope

Dr Benard
Dr François Bénard
New hope is on the horizon for Canadians facing advanced prostate cancer that has become unresponsive to current treatment options.  
Dr François Bénard is conducting a national multi-centre clinical trial with support from the CCS-funded Cancer Clinical Trials Group. The work will accelerate Canadians’ access to a new and promising prostate cancer treatment: radioligand therapy (RLT).  
“RLT uses radiation to locate and destroy prostate cancer cells,” says Dr Bénard. “What makes RLT so exciting is that the radiation is delivered directly and specifically to tumour cells wherever they are in the body.” 
The trial will study outcomes for people with metastatic prostate cancer treated with RLT as compared to standard chemotherapy. In addition, the research will consider practical barriers and healthcare costs for Canadians accessing RLT.  
“Donors to CCS play a key role in fueling discoveries with potential to improve quality of life, and survival, for thousands of Canadians,” says Dr Stuart Edmonds, Executive VP of Mission, Research and Advocacy at CCS. “Thank you for your support of Canada’s most promising prostate cancer research.”